Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR)…
Latest News
-
-
Novocure seeks approval after pancreatic cancer wearable scores at Phase III
Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic…
-
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Cassava Sciences’ stock has dropped by more than 80% after the company revealed its lead and only investigational product simufilam…
-
Sponsors and CROs: getting the right balance is vital
Sponsors rely on contract research organisations (CROs) to ensure a trial runs smoothly at all stages, through planning, execution, and…
-
Neuralink receives Health Canada approval to launch trial of implantable device
Neuralink has received approval from Health Canada to launch the first global trial, ‘Canadian Precise Robotically Implanted Brain-Computer Interface’ (CAN-PRIME),…
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
-
Trump picks vaccine sceptic RFK Jr to lead HHS in new administration
President-elect Donald Trump has appointed Robert F Kennedy Jr, popularly known as RFK Jr, as the secretary of the premier…
-
Amgen speaks out about bone density concerns with obesity drug
Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s…
-
Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
-
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to…
